FOUNDATIONONE™

Patient Name	Report Date	Diagnosis
Agenor, Gethro	**29 March 2013**	**Stomach GIST**

Date of Birth	20 October 1954	**Client**	Boston Medical Center	**Specimen Received**	18 March 2013
Gender	Male	**Ordering Physician**	Eton, Omar	**Specimen Site**	Not Provided
FMI Case #	TRF009601	**Additional Recipient**	Carmen Sarita Peyes	**Date of Collection**	15 March 2013
Medical Record #	2794528	**FMI Client #**	200411	**Specimen Type**	Block
Specimen ID	S13-2531 A4	**Pathologist**	Not Provided		

ABOUT THE TEST:
FoundationOne™ is a next-generation sequencing (NGS) based assay which identifies genomic alterations within hundreds of cancer-related genes.

PATIENT RESULTS

2 genomic alterations

8 therapies associated with potential clinical benefit

0 therapies associated with lack of response

4 clinical trials

TUMOR TYPE: STOMACH GIST

Genomic Alterations Identified†

KIT Q556_V560del
CRKL amplification

Additional Disease-relevant Genes with No Reportable Alterations Detected
PDGFRA

†For a complete list of the genes assayed, please refer to the Appendix

THERAPEUTIC IMPLICATIONS

Genomic Alterations Detected	FDA Approved Therapies (in patient's tumor type)	FDA Approved Therapies (in another tumor type)	Potential Clinical Trials
KIT Q556_V560del	Imatinib Sunitinib	Dasatinib Everolimus Nilotinib Pazopanib Sorafenib Temsirolimus	Yes, see clinical trials section
CRKL amplification	None	Dasatinib	Yes, see clinical trials section

Note: Genomic alterations detected may be associated with activity of certain FDA approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type.

CLINICAL TRIALS TO CONSIDER

IMPORTANT: While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continuously updated and should be investigated by the physician or research staff. This is not meant to be a complete list of available trials. In order to conduct a more thorough search, please go to www.clinicaltrials.gov and use the search terms provided below. For more information about a specific clinical trial, type the NCT ID of the trial indicated below into the search bar.

GENE	RATIONALE FOR POTENTIAL CLINICAL TRIALS
KIT Q556_V560del	KIT activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because Kit activation leads to activation of the PI3K/Akt and mTOR pathways, PI3K and mTOR pathway inhibitors may be relevant in a tumor with Kit activation. Hsp90 inhibitors are also being studied in Phase 2 clinical trials for patients whose tumors are resistant to imatinib and sunitinib. A search of the trial website clinicaltrials.gov, using terms such "KIT", "PI3K", "mTOR", "HSP90", "imatinib", "GIST", and/or "solid tumor", retrieves more than 10 trials that may be relevant for this patient's tumor. Examples of these trials are shown below.

TITLE	PHASE	TARGETS	LOCATIONS	NCT ID
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumour in First Line Medical Treatment	Phase 3	BCR-ABL, KIT, PDGFR	Florida, Georgia, Michigan, New York, Ohio, South Carolina, Wisconsin, Abbeville (France), Avignon (France), Beirut (Lebanon), Besançon (France), Bordeaux (France), Brest (France), Créteil (France), Dijon (France), Dreux (France), Evreux (France), Gap (France), La Roche sur Yon (France), La Rochelle (France), Libourne (France), Lille (France), Lyon (France), Marseille (France), Metn (Lebanon), Montpellier (France), Nantes (France), Orléans (France), Paris (France), Reims (France), Rouen (France), Saida (Lebanon), Saint Brieuc (France), Saint-Cloud (France), St Priez-en-Jarez (France)	NCT00812240
A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib	Phase 1	BCR-ABL, c-kit (CD117), PDGFR, PI3K	Massachusetts, New York, Washington, Alberta (Canada), MI (Italy), Barcelona (Spain), Berlin (Germany), Leiden (Netherlands), Leuven (Belgium), London (United Kingdom), Lyon Cedex (France), Manchester (United Kingdom), Muenchen (Germany), Villejuif Cedex (France)	NCT01468688

CLINICAL TRIALS TO CONSIDER (CONT.)

GENE	RATIONALE FOR POTENTIAL CLINICAL TRIALS
CRKL amplification	Amplification of CRKL has been associated with response to the Src/Bcr-Abl kinase inhibitor BMS354825 (dasatinib) in gastric cancer cell lines, and may predict sensitivity to dasatinib in other tumor types. A search of the trial website clinicaltrials.gov, using terms such as "dasatinib", "GIST", and/or "solid tumor", retrieves fewer than 10 trials that may be relevant for this patient's tumor. Examples of these trials are shown below.

TITLE	PHASE	TARGETS	LOCATIONS	NCT ID
Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction	Phase 1	BCR-ABL, c-kit (CD117), EphA2, PDGFR, SRC	California, Michigan, Texas, Washington	NCT00608361
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors	Phase 1	BCR-ABL, c-kit (CD117), EphA2, PDGFR, SRC, VEGF	Maryland	NCT01445509